Psychedelic Trials Skip the Solution They Already Know

Psychedelic researchers are stuck with an unsolvable problem. Their trials need placebo controls to prove efficacy. The drugs produce intense, unmistakable perceptual shifts that participants recognize instantly, collapsing the blinding entirely.

This isn't new. In 1985, MDMA researchers hit the same wall when the drug's euphoric rush proved impossible to hide, rendering placebo controls useless for years.

Then researchers in the 1990s thought laterally and used active comparator drugs — low-dose amphetamine, methylphenidate — substances that produced noticeable physiological effects without therapeutic benefit. Participants felt something. The blinding worked. The mechanism is simple and brutal. When a drug's action is obviously perceptible, only another active substance can match it.

Current psychedelic trials cite the MDMA precedent and then ignore it. The bottleneck isn't scientific, it's economic. Active comparators cost more and require additional regulatory approval, complicating the story for funders and journals. Researchers stack trials with methodological rot that everyone understands and publishes anyway.

This is how institutions betray their own knowledge. Not through ignorance but through the choice to let cost determine what gets discovered. Teams know what rigor requires but opt for easier instead. The machinery of legitimacy runs on fumes while everyone pretends the engine still works. It's not that we're incapable of better. We're just unwilling to pay for it.